Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

BrainStorm to complete experiments for Harlan Biotech
November 2009
SHARING OPTIONS:

NEW YORK—BrainStorm Cell Therapeutics Inc., a developer of adult stem cell technologies and therapeutics, announced in October that it has entered into a strategic agreement with Harlan Biotech Israel Ltd. (HBI), a Good Laboratory Practice contractor, in order to complete pre-clinical safety experiments for the company's therapy for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. The agreement will allow Brainstorm to complete the experiments required to submit an application to the Helsinki Committee with the Israeli Ministry of Health for starting ALS clinical trials in Israel. HBI will perform preclinical safety experiments using the company's cGMP compliant stem cells. Financial details were not released.        

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.